Bristol-Myers Squibb reported positive results Monday in a crucial immunotherapy trial, using a combination of the two drugs Opdivo and Yervoy to treat patients with a specific type of non-small cell lung cancer patients.
But previously undisclosed changes made by Bristol to the study, known as Checkmate-227, are raising questions about the validity and strength of the results.
This isn’t quite true. TMB was added as co-primary endpoint before the study enrollment stopped. PDL is still in trials which is continuing. TMB data on progression free survival showed enough impact it hit endpoint early so the data was released
Comments are closed.